Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 8Completed 5Active not recruiting 5Recruiting 3Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Sarcoma 1Recurrence 1Neoplasm Metastasis 1Brest Cancer 1

Interventions

Carboplatin 12pembrolizumab 8Paclitaxel 8Cyclophosphamide 8toripalimab 4sacituzumab govitecan 4olaparib 4Epirubicin 4Drug Therapy 4Doxorubicin 4eribulin 3Capecitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2Radiotherapy 2Injections 2Gemcitabine 2taxane 1poly ICLC 1pirfenidone 1palbociclib 1ivarmacitinib 1inavolisib 1fludarabine 1daratumumab 1camrelizumab 1axatilimab 1anlotinib 1aldesleukin 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Triple Negative Breast Neoplasms × eribulin × Clear all
NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
26 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Fudan University

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06202313 2024-01-11

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Shengjing Hospital

Phase 2 Not yet recruiting
128 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡